Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Galida NDA Delayed Until 2007 Due To PPAR Safety Concerns

Executive Summary

AstraZeneca will delay an NDA filing for its dual PPAR Galida (tesaglitazar) until 2007 in order to gather two years of long-term follow-up data

You may also be interested in...



Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says

Advisory committees should be strengthened to better scrutinize safety data and improve advice given to FDA, Steve Nissen (Cleveland Clinic Foundation) said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System

Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says

Advisory committees should be strengthened to better scrutinize safety data and improve advice given to FDA, Steve Nissen (Cleveland Clinic Foundation) said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System

Pargluva Panic: Need For Additional Trial Prompts Merck To Drop Partnership

Bristol-Myers Squibb remains in discussions with FDA about what clinical studies would be required to address concerns about the cardiovascular safety profile of its type 2 diabetes treatment candidate Pargluva (muraglitazar)

Related Content

UsernamePublicRestriction

Register

PS044783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel